Respiratory Research Analysis
Q1 2026 respiratory science converged on host-directed biology, near-patient precision tools, and a transmission-to-immunogen continuum. Foundational COPD advances (SERPING1 as a causal modulator and a cellular/spatial atlas) linked tissue states to blood biomarkers and tractable therapeutic targets. At-scale implementation and bedside studies (digital antibiotic stewardship; rapid procalcitonin in ED sepsis care; one-hour IL-6/sTNFR1 ARDS phenotyping) delivered outcome gains and actionable stra
Summary
Q1 2026 respiratory science converged on host-directed biology, near-patient precision tools, and a transmission-to-immunogen continuum. Foundational COPD advances (SERPING1 as a causal modulator and a cellular/spatial atlas) linked tissue states to blood biomarkers and tractable therapeutic targets. At-scale implementation and bedside studies (digital antibiotic stewardship; rapid procalcitonin in ED sepsis care; one-hour IL-6/sTNFR1 ARDS phenotyping) delivered outcome gains and actionable stratification without increasing antibiotic use. Virology and immunology progressed with direct human quantification of infectious aerosol emissions and RBS-mimicking broadly neutralizing antibodies against influenza B, aligning with a mechanistic lung–heart axis for influenza-associated cardiac injury. Interventional pulmonology advanced via EBUS-guided mediastinal cryobiopsy outperforming TBNA, while nerandomilast signaled disease-modifying potential in progressive pulmonary fibrosis. Cross-month threads connected tissue-to-blood mapping, rapid phenotyping, and structure-guided antivirals, setting the agenda for phenotype-stratified trials and drift-resilient immunogens.
Selected Articles
1. Multiomics Mendelian randomization identifies serpin family G member 1 as a chronic obstructive pulmonary disease modulator.
Integrated multi-omics Mendelian randomization, longitudinal cohorts, and AAV-mediated overexpression in smoke-exposed mice nominate SERPING1 as a causal COPD modulator; higher circulating SERPING1 associated with slower early FEV1 decline and improved lung integrity in vivo.
Impact: Bridges genetic causality to in vivo validation, providing a tractable complement-regulatory target and immediate biomarker utility for COPD risk stratification.
Clinical Implications: SERPING1 can inform predictive blood panels for early FEV1 decline and motivate ancestry-stratified, host-directed trials of complement modulation in COPD.
Key Findings
- pQTL/eQTL-integrated MR supports causal links between SERPING1, COPD risk reduction, and lung function.
- Higher circulating SERPING1 associates with slower early FEV1 decline in UK Biobank and ECOPD.
- AAV-mediated SERPING1 overexpression improves lung function and alveolar integrity in smoke-exposed mice.
2. Aberrant cellular communities underlying disease heterogeneity in chronic obstructive pulmonary disease.
A 1.5M-nucleus COPD atlas integrated with spatial transcriptomics and plasma proteomics maps disease-linked cell states, spatial niches, and circulating biomarkers, enabling biomarker-driven stratification and therapeutic hypotheses.
Impact: Provides a high-resolution resource that operationalizes tissue insights into accessible blood biomarkers and targetable networks for stratified trials.
Clinical Implications: Supports development of blood-based panels for COPD stratification and prioritizes interventions against profibrotic/remodeling niches.
Key Findings
- Defined emergent cell states correlating with lung function and symptoms.
- Identified spatial pathological niches with co-occurring cell communities.
- Nominated plasma biomarkers reflecting pathological cell states and ECM remodeling.
3. Controlled human influenza infection reveals heterogeneous expulsion of infectious virus into air.
Using a modular sampling tunnel, investigators cultured, quantified, and sequenced infectious influenza virus directly from human exhaled particles, revealing orders-of-magnitude heterogeneity in emissions correlated with clinical and virologic markers.
Impact: Provides rare, direct human infectious aerosol data that refine transmission risk models and enable targeted IPC strategies.
Clinical Implications: Supports risk-stratified masking, ventilation, and testing policies that account for high emitters and symptom-linked peaks.
Key Findings
- Culture-based quantification and sequencing of infectious virus from exhaled aerosols.
- Emission varied by orders of magnitude across individuals.
- Emission correlated with infectious loads in saliva/nasopharynx and with symptoms.
4. Effects of a comprehensive antibiotic stewardship program on antibiotic prescribing for acute respiratory infections in rural facilities: a cluster randomized trial.
A cluster RCT across 34 township hospitals showed an EMR-embedded, multi-component stewardship package cut ARI antibiotic prescribing from 71% to 26% without increasing 30-day respiratory or sepsis hospitalizations.
Impact: Delivers randomized, scalable evidence that digital team-based stewardship can sharply reduce inappropriate antibiotic use for respiratory infections without safety trade-offs.
Clinical Implications: Primary care networks can adopt EMR prompts, audit-feedback, and patient education to curb ARI overprescribing within AMR strategies.
Key Findings
- Antibiotic prescribing fell from 71% to 26% with the intervention.
- No increase in 30-day respiratory or sepsis hospitalizations.
- Multi-component design: EMR prompts, clinician training, peer-review feedback, patient education.
5. Human monoclonal antibodies isolated after seasonal vaccination broadly neutralize antigenically drifted influenza B viruses.
Two human bnAbs isolated post-vaccination broadly neutralize contemporary influenza B lineages and protect in vivo; structures show HCDR3 insertion into the HA RBS that sterically mimics sialic acid, conferring drift resilience.
Impact: Defines a drift-resilient neutralization mechanism at the HA RBS and offers candidates and blueprints for next-generation influenza B vaccines/therapeutics.
Clinical Implications: Guides immunogen design toward conserved RBS features and supports antibody therapeutics robust to prevailing HA-136 variants.
Key Findings
- Two bnAbs neutralized both Victoria and Yamagata lineages and protected in vivo.
- Structures revealed HCDR3 insertion into the RBS mimicking sialic acid.
- Explained resilience to K136E drift in Victoria HA.
6. EBUS-guided transbronchial mediastinal cryobiopsy for diagnosing non-metastatic lymphadenopathy: A randomized controlled trial.
A multicenter RCT demonstrated that EBUS-guided mediastinal cryobiopsy achieved higher diagnostic yield than EBUS-TBNA for benign mediastinal/hilar lymphadenopathy with acceptable safety.
Impact: First randomized evidence that cryobiopsy outperforms TBNA in benign nodal disease, enabling immediate updates to diagnostic pathways and reducing nondiagnostic procedures.
Clinical Implications: Adopt EBUS-guided cryobiopsy as first-line when benign etiologies are suspected (e.g., sarcoidosis) to improve yield and expedite definitive management.
Key Findings
- Diagnostic yield: 97.1% vs 79.9% for EBUS-TBMC vs EBUS-TBNA.
- Higher sensitivity for sarcoidosis with cryobiopsy.
- Acceptable safety with only grade 1 airway bleeding.
7. Influenza hijacks myeloid cells to inflict type-I interferon-fueled damage in the heart.
After pulmonary influenza, CCR2-high pro-DC3 myeloid cells traffic to the heart, transmit virus to cardiomyocytes, and trigger IFN-I/IFNAR1-dependent injury; cardiomyocyte-specific IFNAR1 dampening preserved cardiac function without impairing lung antiviral defense.
Impact: Reveals a targetable lung–heart axis and positions cardiomyocyte IFNAR1 as an organ-specific node to mitigate influenza cardiac complications.
Clinical Implications: Motivates development of transient, cardiomyocyte-targeted IFN-I modulators and evaluation of circulating CCR2+ pro-DC3 signatures for early cardiac risk stratification.
Key Findings
- CCR2-high pro-DC3 cells become infected post-influenza and home to the heart.
- Myeloid-to-cardiomyocyte viral transfer induces IFN-I/IFNAR1-dependent injury.
- Cardiomyocyte-specific IFNAR1 dampening preserves function without compromising lung immunity.
8. Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PRONTO): a multicentre, randomised, controlled, open-label, phase 3 trial.
In a pragmatic phase 3 trial, adding rapid procalcitonin to NEWS2-based ED care did not change 3-hour antibiotic initiation but significantly reduced 28-day mortality, meeting non-inferiority and superiority without more adverse events.
Impact: Shows survival benefit from integrating a rapid biomarker into routine ED assessment for suspected sepsis, demonstrating scalable, pathway-level impact.
Clinical Implications: Integrate procalcitonin into ED workflows with stewardship monitoring to reduce mortality without increasing early antibiotic use.
Key Findings
- Reduced 28-day mortality with procalcitonin-guided care.
- Similar 3-hour IV antibiotic initiation between groups.
- No increase in adverse events; high uptake of PCT-informed decisions.
9. Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial.
In 1,176 patients with progressive pulmonary fibrosis, nerandomilast reduced the composite risk of first acute ILD exacerbation, respiratory hospitalization, or death versus placebo over extended follow-up with favorable tolerability.
Impact: Provides randomized evidence of disease-modifying potential across hard clinical endpoints in PPF.
Clinical Implications: Consider nerandomilast—particularly off nintedanib background—to reduce AE-ILD, respiratory hospitalization, and death with structured long-term safety monitoring.
Key Findings
- Reduced composite AE-ILD/respiratory hospitalization/death vs placebo.
- Larger effect without background nintedanib.
- Favorable safety and tolerability over extended follow-up.
10. Bedside identification of subphenotypes in acute respiratory failure (PHIND): a multicentre, observational cohort study.
A near-patient immunoanalyser measuring IL-6 and sTNFR1 plus minimal clinical data classified ARDS/AHRF into hyper- versus hypoinflammatory groups within ~1 hour, with strong mortality separation.
Impact: Delivers prospective, bedside-capable ARDS subphenotyping with clear prognostic separation, enabling phenotype-stratified trials and actionable ICU decisions.
Clinical Implications: Use rapid IL-6/sTNFR1 testing to stratify ARDS patients for prognosis and trial enrollment; prioritize hyperinflammatory patients for immunomodulatory strategies.
Key Findings
- One-hour near-patient testing separated hyper- and hypoinflammatory phenotypes.
- Hyperinflammatory phenotype had substantially higher 60-day mortality.
- Feasibility and turnaround demonstrated across multiple centers.